Cencora
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
Track Cencora in real time with a live news feed covering Cencora stock news, official press releases, company announcements, and an archive of historical Cencora news. ...more
Loading news...
Loading more...
4:30 PM | Wednesday | Jul 1, 2026
Sign in to download news snippet
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m.
ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief.
No data available for this time period.
Change the time range to see results.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m.
ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control. Developed with input from customer advisory boards and specialty care providers, the updated platform combines redesigned physical infrastructure with software and interface e.
Read full article
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha (Sam) Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026. "During her seven years of leadership, Silvana has made critical, lasting contributions to Cencora durin.
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Read full article
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel). The collaboration is designed to support efficient access to the cell therapies at the increasing number of authorized treatment centers in the U.
S., including health systems and community oncology practices.
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Read full article
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms.
Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms.
Boratto is an experienced pub.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.
90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company's previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end.
No data available for this time period.
Change the time range to see results.